Overview
The History
Leadership Team
William C. Weldon
Robert A. Ingram
Christopher A. Viehbacher
H. Edward Hanway
Martin J. Murphy
Gregory A. Curt
Mace Rothenberg
Judy O'Hagan
John N. Dornan
Task Forces at a Glance
Vendor Endorsement Policy
FAQs
News
Press Releases
Videos
Task Forces at a Glance
The
CEO Cancer Gold Standard
™ created by the Member CEOs in 2004, is a comprehensive, workplace-based initiative that encourages state-of-the-science prevention, early diagnosis and quality treatment. The Gold Standard addresses three specific goals:
Risk Reduction
, or reducing the risk for cancer,
Early Detection
, when detecting it at the earliest possible stage can improve outcomes, and
Quality Care
, or ensuring access to high-quality treatment, including participation in clinical trials.
The focus is in five critical areas, referred to as “pillars”, and they are aligned with the major goals:
Risk Reduction through Lifestyle Change
Tobacco Use
Diet & Nutrition
Physical Activity
Early Detection
Prevention, Screening & Early Detection
Quality Care
Access to Quality Treatment & Clinical Trials
For each pillar, organizations that adopt the Gold Standard maintain a
culture
that encourages healthy lifestyles and provides support when a diagnosis of cancer becomes a reality. In addition, they offer
benefits and programs
that lower the risk of cancer, detect it earlier, and provide access to the best-available care. Organizations that become accredited as “
CEO Cancer Gold Standard
™ companies” must satisfy the requirements of all five pillars. Please visit
www.cancergoldstandard.com
for much more information about the Gold Standard, including how to apply for accreditation.
The
Life Sciences Consortium (LSC)
was formed in 2005 by the
CEO Roundtable on Cancer
as a means of bringing together leading oncology pharmaceutical/biotechnology companies to build collaboration in cancer drug development. The goal of these collaborations is a transformation in research and development that will effectively deliver new agents to prevent and treat cancer to people who need them and fulfill the promise of our emerging understanding of cancer biology. This collaboration focuses on exploring and solving issues common to all cancer companies engaged in drug discovery and development that cannot be solved by any company alone. Please visit
www.ceo-lsc.org
for much more information about the
Life Sciences Consortium
and its progress.
July 29 2010
Blue Cross Blue Shield of North Carolina awarded CEO Cancer Gold StandardTM accreditation
CARY, NC (July 29, 2010) – Blue Cross and Blue Shield of North Carolina (BCBSNC) has received CEO Cancer Gold Standard™ accreditation, recognizing the organization’s commitment to reducing the risk of cancer for employees and their families by promoting healthy lifestyle choices, encouraging early detection through cancer screenings, and ensuring access to quality treatment.
Read More
June 21 2010
Publicis awarded CEO Cancer Gold StandardTM accreditation
CARY, NC (June 21, 2010) – Publicis Healthcare Communications Group (PHCG), the world's largest healthcare communications group, has received CEO Cancer Gold Standard™ accreditation, recognizing the organization’s commitment to reducing the risk of cancer for employees and their families by promoting healthy lifestyle choices, encouraging early detection through cancer screenings, and ensuring access to quality treatment.
Read More
January 21 2010
The
CEO Roundtable on Cancer
Salutes SAS and Meridian Health
The CEO Roundtable on Cancer, the nonprofit organization of cancer-fighting CEOs who created the CEO Cancer Gold Standard, salutes SAS Institute for being ranked No.1 on FORTUNE magazine’s annual “100 Best Companies to Work For” list.
Read More
Contact Us
Privacy Policy
Terms Of Use
Technical Support
Site Map
Copyright 2010